Latest news

• Janssen’s single tablet Symtuza gains NHS England funding 

  Biktarvy is a combination of integrase inhibitor bictegravir with Gilead’s existing blockbuster Descovy, a combination of emtricitabine (FTC) and tenofovir alafenamide (TAF).

• ViiV chalks up another win for two-drug HIV regimen

  Gilead’s new fixed-dose Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) triple.

• GSK two-drug trial in untreated HIV raises Gilead rivalry

  The recent FDA approval of single-tablet triple Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) in the US and Europe is central to Gilead’s push-back, with some analysts predicting it could

• Gilead’s Biktarvy gets European approval, setting up battle with GSK

  The single tablet regimen (STR) is a combination of integrase inhibitor bictegravir with Gilead’s already blockbuster Descovy, a combination of emtricitabine (FTC) and tenofovir alafenamide (TAF).

• The year of the blockbuster

  Biktarvy (tenofovir alafenamide emtricitabine bictegravir) from Gilead:Gilead’s HIV triplet comprising the nucleoside reverse transcriptase inhibitor tenofovir alafenamide, the nucleoside reverse transcriptase inhibitor emtricitabine and the novel